Denise Kruzikas
YOU?
Author Swipe
View article: Real-World Analysis of Patient Characteristics, Adverse Events, and Economic Burden Among Patients with Giant Cell Arteritis Treated with Glucocorticoids
Real-World Analysis of Patient Characteristics, Adverse Events, and Economic Burden Among Patients with Giant Cell Arteritis Treated with Glucocorticoids Open
Patients newly diagnosed with GCA and newly treated with GCs experience significantly higher rates of GRAEs in every category and two-fold higher healthcare costs. These data reflect the medical and financial burden for patients with GCA r…
View article: ABS1062 IMPACT OF CLINICALLY IMPORTANT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ON DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH UPADACITINIB OR PLACEBO: RESULTS FROM THE PHASE 2 SLEek STUDY
ABS1062 IMPACT OF CLINICALLY IMPORTANT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ON DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH UPADACITINIB OR PLACEBO: RESULTS FROM THE PHASE 2 SLEek STUDY Open
View article: ABS0880 A REAL-WORLD PERSPECTIVE ON THE ASSOCIATION OF IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE OUTCOMES AND DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS
ABS0880 A REAL-WORLD PERSPECTIVE ON THE ASSOCIATION OF IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE OUTCOMES AND DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS Open
View article: ASSOCIATION BETWEEN IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE OUTCOMES AND DISEASE ACTIVITY IN SLE: A REAL-WORLD COHORT STUDY
ASSOCIATION BETWEEN IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE OUTCOMES AND DISEASE ACTIVITY IN SLE: A REAL-WORLD COHORT STUDY Open
PV178 / #702 Poster Topic: AS19 - Patient-Reported Outcome Measures Background/Purpose Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder associated with significant morbidity and mortality. The use of patient-reported out…
View article: Efficacy, Safety, Pharmacokinetics, and Immunogenicity of <scp>ABBV</scp>‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of <span>ABBV</span>‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial Open
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated …
View article: OP0139 EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
OP0139 EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL Open
View article: Supplementary Figure 1 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Figure 1 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 60K, Appendix Figure A: Change in Median Procedure Cost between 2001 and 2006.
View article: Supplementary Table 2 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 2 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 59K, Appendix Table B: Procedures by Age Group.
View article: Supplementary Table 5 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 5 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 59K, Appendix Table E: Median (Mean SD) Cost Per Procedure in 2005 for HPV Vaccination Target Age Groups.
View article: Supplementary Figure 1 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Figure 1 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 60K, Appendix Figure A: Change in Median Procedure Cost between 2001 and 2006.
View article: Supplementary Table 1 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 1 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 69K, Appendix Table A: Codes Used to Identify Procedures.
View article: Supplementary Table 4 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 4 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 58K, Appendix Table D: Median (Mean SD) Cost Per Procedure, 2001-2006, by Age Group.
View article: Data from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Data from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
Background: Oncogenic types of human papillomavirus (HPV) have been linked to 99.7% of cervical cancer cases worldwide.Methods: This retrospective claims-based analysis was conducted to assess patterns of use and costs associ…
View article: Supplementary Table 4 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 4 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 58K, Appendix Table D: Median (Mean SD) Cost Per Procedure, 2001-2006, by Age Group.
View article: Supplementary Table 3 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 3 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 12K, Appendix Table C: Procedure Rates Among Target Age Groups.
View article: Supplementary Table 5 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 5 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 59K, Appendix Table E: Median (Mean SD) Cost Per Procedure in 2005 for HPV Vaccination Target Age Groups.
View article: Supplementary Table 1 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 1 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 69K, Appendix Table A: Codes Used to Identify Procedures.
View article: Supplementary Table 3 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 3 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 12K, Appendix Table C: Procedure Rates Among Target Age Groups.
View article: Data from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Data from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
Background: Oncogenic types of human papillomavirus (HPV) have been linked to 99.7% of cervical cancer cases worldwide.Methods: This retrospective claims-based analysis was conducted to assess patterns of use and costs associ…
View article: Supplementary Table 2 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions
Supplementary Table 2 from Costs Associated with Management of Cervical Human Papillomavirus-Related Conditions Open
PDF file, 59K, Appendix Table B: Procedures by Age Group.
View article: Geographic Variations in Diagnosis and Treatment of Ankylosing Spondylitis in the United States: A Real-World Study
Geographic Variations in Diagnosis and Treatment of Ankylosing Spondylitis in the United States: A Real-World Study Open
AS diagnostic prevalence is increasing nationally, though it remains low among some states. bDMARD/tsDMARDs use was more common among patients treated by rheumatologists. Opioid and corticosteroid use is decreasing, though national rates r…
View article: HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications
HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications Open
BACKGROUND: The Institute for Clinical and Economic Review (ICER) is a prominent health technology assessment (HTA) entity in the United States that considers costs and applies economic analyses to derive price-based recommendations…
View article: PMU75 EMERGING TRENDS IN US HTA: A SYSTEMATIC REVIEW OF ICER VALUE ASSESSMENTS TO IDENTIFY FACTORS ASSOCIATED WITH RECOMMENDATIONS
PMU75 EMERGING TRENDS IN US HTA: A SYSTEMATIC REVIEW OF ICER VALUE ASSESSMENTS TO IDENTIFY FACTORS ASSOCIATED WITH RECOMMENDATIONS Open